RxDoctor Payments Data

Gary Feldman, DPM

Primary Podiatric Medicine · Bethesda, MDNPI 1891717377

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (44.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Arthrex at 43.5% of the total. Reporting peaked in 2019 at $2,632 and has fallen 99.3% since, to $18 in 2024.

$4,602in general payments, 2019–2025

Across 26 payments — averaging $176.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$2K
  • Supreme Orthopedic Systems, LLC$2K
  • Zimmer Biomet$380
  • Ossio Inc$156
  • Acumed LLC$142
  • Stryker$92
  • plus $73 from 3 others

What the payments were for

  • Speaking & faculty fees$2,00043%
  • Food & beverage$54212%
  • Education$2,06045%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Arthrex1$2,000
Supreme Orthopedic Systems, LLC5$1,759
Zimmer Biomet7$380
Ossio Inc2$156
Acumed LLC1$142
Stryker(2 entities)6$92
Smith+Nephew2$38
Amgen1$19
Bioventus LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few primary podiatric medicine providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$56,263
Medicare patients
182
Services billed
1,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylprednisolone23$112

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →